Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
<p>Abstract</p> <p>Background</p> <p>Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy.</p> <p>Methods</p> <p>We evaluated the efficacy and safety of the SCIG Vivaglobin<sup>® </sup...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-06-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | http://www.eurjmedres.com/content/15/6/238 |
| _version_ | 1811318324736294912 |
|---|---|
| author | Hoffmann F Grimbacher B Thiel J Peter HH Belohradsky BH |
| author_facet | Hoffmann F Grimbacher B Thiel J Peter HH Belohradsky BH |
| author_sort | Hoffmann F |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy.</p> <p>Methods</p> <p>We evaluated the efficacy and safety of the SCIG Vivaglobin<sup>® </sup>(formerly known as Beriglobin<sup>® </sup>SC) under real-life conditions in a post-marketing observational study in 82 patients with primary or secondary antibody deficiencies. Health-related quality of life (HRQoL) was evaluated in a subset of 30 patients previously treated with IVIG (including 11 children < 14 years) using the Short Form 36 (SF-36) for patients ≥ 14 years of age (adults) and the Child Health Questionnaire - Parental Form 50 (CHQ-PF50) for children < 14 years of age. Treatment preferences were assessed in adults.</p> <p>Results</p> <p>The mean serum immunoglobulin G (IgG) trough level during SCIG treatment (7.5 g/L) was higher than during previous IVIG treatment (6.6 g/L; p < 0.01). The investigators assessed the efficacy of SCIG therapy as "excellent" in 89% of patients. No systemic adverse drug reactions were observed. Improvements by ≥ 5 points were observed in 5 of 8 SF36 subscales and in 6 of 12 CHQ-PF50 subscales. Statistically significant improvements (p ≤ 0.05) were observed for the SF-36 subscales of bodily pain, general health perceptions, and vitality (adults), and for the CHQ-PF50 subscales of general health perceptions, parental impact - time, parental impact - emotional, and family activities (children). Patients preferred SCIG over IVIG therapy (92%) and home therapy over therapy at the clinic/physician (83%).</p> <p>Conclusion</p> <p>This study confirms that therapy with Vivaglobin<sup>® </sup>at home is effective, safe, well tolerated, and improves quality of life in patients with antibody deficiency.</p> |
| first_indexed | 2024-04-13T12:23:39Z |
| format | Article |
| id | doaj.art-be0ecefd9bfb4f43956eb01b369fd610 |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-04-13T12:23:39Z |
| publishDate | 2010-06-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-be0ecefd9bfb4f43956eb01b369fd6102022-12-22T02:47:05ZengBMCEuropean Journal of Medical Research2047-783X2010-06-0115623810.1186/2047-783X-15-6-238Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiencyHoffmann FGrimbacher BThiel JPeter HHBelohradsky BH<p>Abstract</p> <p>Background</p> <p>Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy.</p> <p>Methods</p> <p>We evaluated the efficacy and safety of the SCIG Vivaglobin<sup>® </sup>(formerly known as Beriglobin<sup>® </sup>SC) under real-life conditions in a post-marketing observational study in 82 patients with primary or secondary antibody deficiencies. Health-related quality of life (HRQoL) was evaluated in a subset of 30 patients previously treated with IVIG (including 11 children < 14 years) using the Short Form 36 (SF-36) for patients ≥ 14 years of age (adults) and the Child Health Questionnaire - Parental Form 50 (CHQ-PF50) for children < 14 years of age. Treatment preferences were assessed in adults.</p> <p>Results</p> <p>The mean serum immunoglobulin G (IgG) trough level during SCIG treatment (7.5 g/L) was higher than during previous IVIG treatment (6.6 g/L; p < 0.01). The investigators assessed the efficacy of SCIG therapy as "excellent" in 89% of patients. No systemic adverse drug reactions were observed. Improvements by ≥ 5 points were observed in 5 of 8 SF36 subscales and in 6 of 12 CHQ-PF50 subscales. Statistically significant improvements (p ≤ 0.05) were observed for the SF-36 subscales of bodily pain, general health perceptions, and vitality (adults), and for the CHQ-PF50 subscales of general health perceptions, parental impact - time, parental impact - emotional, and family activities (children). Patients preferred SCIG over IVIG therapy (92%) and home therapy over therapy at the clinic/physician (83%).</p> <p>Conclusion</p> <p>This study confirms that therapy with Vivaglobin<sup>® </sup>at home is effective, safe, well tolerated, and improves quality of life in patients with antibody deficiency.</p>http://www.eurjmedres.com/content/15/6/238antibody deficiencysubcutaneous immunoglobulin therapyquality of lifechildrenadults |
| spellingShingle | Hoffmann F Grimbacher B Thiel J Peter HH Belohradsky BH Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency European Journal of Medical Research antibody deficiency subcutaneous immunoglobulin therapy quality of life children adults |
| title | Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency |
| title_full | Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency |
| title_fullStr | Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency |
| title_full_unstemmed | Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency |
| title_short | Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency |
| title_sort | home based subcutaneous immunoglobulin g replacement therapy under real life conditions in children and adults with antibody deficiency |
| topic | antibody deficiency subcutaneous immunoglobulin therapy quality of life children adults |
| url | http://www.eurjmedres.com/content/15/6/238 |
| work_keys_str_mv | AT hoffmannf homebasedsubcutaneousimmunoglobulingreplacementtherapyunderreallifeconditionsinchildrenandadultswithantibodydeficiency AT grimbacherb homebasedsubcutaneousimmunoglobulingreplacementtherapyunderreallifeconditionsinchildrenandadultswithantibodydeficiency AT thielj homebasedsubcutaneousimmunoglobulingreplacementtherapyunderreallifeconditionsinchildrenandadultswithantibodydeficiency AT peterhh homebasedsubcutaneousimmunoglobulingreplacementtherapyunderreallifeconditionsinchildrenandadultswithantibodydeficiency AT belohradskybh homebasedsubcutaneousimmunoglobulingreplacementtherapyunderreallifeconditionsinchildrenandadultswithantibodydeficiency |